Although substantial progress has been made in cancer biology and treatment, clinical
outcomes of bladder carcinoma (BC) patients are still not satisfactory. The tumor …

The molecular landscape in non-muscle-invasive bladder cancer (NMIBC) is characterized
by large biological heterogeneity with variable clinical outcomes. Here, we perform an …

Bladder cancer (BC) can be divided into two subgroups depending on invasion of the
muscular layer: non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder …

Simple Summary Bladder cancer (BC) is a common cancer that causes high morbidity and
mortality among affected patients. As a carcinogen-driven cancer, molecular oncology of BC …

Muscle invasive bladder cancers (BCs) can be divided into 2 major subgroups-
basal/squamous (BASQ) tumors and luminal tumors. Since Pparg has low or undetectable …

Lung squamous cell carcinoma (LSCC) is the most common subtype of non-small cell lung
cancer. Immunotherapy has become an effective treatment in recent years, while patients …

PURPOSE Immune checkpoint blockade (ICB) therapy has significantly improved clinical
outcomes in bladder cancer. Identification of correlates of benefit is critical to select …

Bladder urothelial carcinoma (BC) is a fatal invasive malignancy and the most common
malignancy of the urinary system. In the current study, we investigated the function and …

Purpose: Although neoadjuvant chemotherapy is associated with a survival advantage in
pure urothelial, muscle invasive bladder cancer, the role of neoadjuvant chemotherapy is …

The global incidence of bladder cancer is more than half a million diagnoses each year.
Bladder cancer can be categorized into non-muscle-invasive bladder cancer (NMIBC) …